Literature DB >> 33641674

COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma.

Felix Behling1,2, Elisa Suhm3,4, Vanessa Ries3,4, Vítor Moura Gonçalves3,5, Ghazaleh Tabatabai3,4,6,7,8, Marcos Tatagiba3,4, Jens Schittenhelm4,9.   

Abstract

OBJECTIVE: Vestibular schwannomas (VS) are benign slow growing tumors arising from the vestibular nerve. The role of cyclooxygenase 2 (COX2) in tumor development of growth has been addressed in a few studies with contradictory results and suggestions. We recently analyzed the immunohistochemical expression of COX2 in 1044 VS samples and described an association of higher COX2 expression with proliferation but found no influence by regular intake of acetylsalicylic acid. We now collected volumetric radiographic data of the preoperative tumor volume and growth to further test the role of COX2 in VS growth.
METHODS: Preoperative images of 898 primary sporadic vestibular schwannomas were assessed, and sufficient preoperative imaging was used for the volumetric measurement preoperative tumor volume (n = 747) and preoperative relative tumor growth (n = 171). Clinical parameters and results of the immunohistochemical expression of COX2 and MIB1 in resected tumor tissue samples were obtained from our prior study. ANOVA, CART-analysis and multivariate nominal logistic regression were used for statistical analysis.
RESULTS: Larger preoperative tumor volumes were observed with tumors of younger patients (p = 0.0288) and with higher COX2 expression scores (p < 0.0001). Higher MIB1 expression was associated with smaller tumors (p = 0.0149) but with increased radiographic tumor growth (p = 0.0003). Patients of older age had tumors with slower growth rates (p = 0.0311). In the multivariate analysis only MIB1 expression was an independent significant factor regarding tumor growth (p = 0.0002).
CONCLUSIONS: Higher expression of COX2 in schwannoma is associated with an increased preoperative tumor volume but not with radiographic tumor growth over time.

Entities:  

Keywords:  Acoustic neuroma; COX2; MIB1; Tissue microarray; Vestibular schwannoma; Volumetric tumor growth

Year:  2021        PMID: 33641674      PMCID: PMC7919305          DOI: 10.1186/s42466-021-00111-6

Source DB:  PubMed          Journal:  Neurol Res Pract        ISSN: 2524-3489


  22 in total

Review 1.  COX-2 inhibitors in cancer treatment and prevention, a recent development.

Authors:  Xiao-Chun Xu
Journal:  Anticancer Drugs       Date:  2002-02       Impact factor: 2.248

2.  Implications of Vestibular Schwannoma Consistency: Analysis of 140 Cases Regarding Radiologic and Clinical Features.

Authors:  Ahmed R Rizk; Abbas Adam; Isabel Gugel; Jens Schittenhelm; Marcos Tatagiba; Florian H Ebner
Journal:  World Neurosurg       Date:  2016-11-24       Impact factor: 2.104

3.  Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas.

Authors:  Bujung Hong; Claudia A Krusche; Kerstin Schwabe; Sabrina Friedrich; Rüdiger Klein; Joachim K Krauss; Makoto Nakamura
Journal:  Neurosurgery       Date:  2011-04       Impact factor: 4.654

4.  Immunophenotype of Vestibular Schwannomas.

Authors:  Wenya Linda Bi; Saksham Gupta; Yu Mei; Sally Al Abdulmohsen; Alexandra Giantini Larsen; Prashin Unadkat; Shakti Ramkissoon; Malak Abedalthagafi; Ian F Dunn
Journal:  Otol Neurotol       Date:  2020-12       Impact factor: 2.311

5.  Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.

Authors:  Victor M Lu; Krishnan Ravindran; Christopher S Graffeo; Avital Perry; Jamie J Van Gompel; David J Daniels; Michael J Link
Journal:  J Neurooncol       Date:  2019-06-28       Impact factor: 4.130

Review 6.  Celecoxib in Cancer Therapy and Prevention - Review.

Authors:  Natalia Tołoczko-Iwaniuk; Dorota Dziemiańczyk-Pakieła; Beata Klaudia Nowaszewska; Katarzyna Celińska-Janowicz; Wojciech Miltyk
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

7.  Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

Authors:  Scott R Plotkin; Dan G Duda; Alona Muzikansky; Jeffrey Allen; Jaishri Blakeley; Tena Rosser; Jian L Campian; D Wade Clapp; Michael J Fisher; James Tonsgard; Nicole Ullrich; Coretta Thomas; Gary Cutter; Bruce Korf; Roger Packer; Matthias A Karajannis
Journal:  J Clin Oncol       Date:  2019-10-18       Impact factor: 44.544

Review 8.  The inflammatory microenvironment in vestibular schwannoma.

Authors:  Cathal John Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd Gareth Evans; Federico Roncaroli; David Brough; Andrew Thomas King; David Coope; Omar Nathan Pathmanaban
Journal:  Neurooncol Adv       Date:  2020-02-27

9.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Authors:  Quinn T Ostrom; Nirav Patil; Gino Cioffi; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-10-30       Impact factor: 12.300

10.  Surgical outcome in cystic vestibular schwannomas.

Authors:  Suresh Nair; Sachin S Baldawa; Chittur Viswanathan Gopalakrishnan; Girish Menon; Vazhayil Vikas; Jayanand B Sudhir
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep
View more
  1 in total

Review 1.  Transition of a vestibular schwannoma to a malignant peripheral nerve sheath tumor with loss of H3K27 trimethylation after radiosurgery-a case report and review of the literature.

Authors:  Felix Behling; Imane Bersali; Antonio Santacroce; Johann Hempel; Kosmas Kandilaris; Jens Schittenhelm; Marcos Tatagiba
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 2.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.